Argonautica Private Wealth Management Inc. Sells 540 Shares of DexCom, Inc. (NASDAQ:DXCM)

Argonautica Private Wealth Management Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,776 shares of the medical device company’s stock after selling 540 shares during the quarter. Argonautica Private Wealth Management Inc.’s holdings in DexCom were worth $449,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter valued at $25,000. Heck Capital Advisors LLC acquired a new stake in DexCom in the 4th quarter valued at $38,000. Midwest Capital Advisors LLC bought a new position in shares of DexCom in the fourth quarter valued at $54,000. RPg Family Wealth Advisory LLC purchased a new position in DexCom during the third quarter worth about $57,000. Finally, Rothschild Investment LLC grew its holdings in shares of DexCom by 250.5% in the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock valued at $58,000 after acquiring an additional 536 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $99.06.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 in the last quarter. 0.30% of the stock is owned by insiders.

DexCom Stock Performance

Shares of DXCM opened at $88.32 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market capitalization of $34.51 billion, a price-to-earnings ratio of 61.76, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock’s 50-day simple moving average is $83.99 and its 200 day simple moving average is $76.38.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.